EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor DEBIO 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): the WIN-B study

Results of a Patient-Level Pooled Analysis of Three Studies of Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with Active Brain Metastases

Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA) + Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2- Advanced Breast Cancer (aBC) Patients (pts) with ESR1-mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

Impact of time to progression (TTP) on CDK4/6 inhibitor (CDK4/6i) therapy on progression-free survival (PFS) in HR+/HER2-/PIK3CA-mutated advanced breast cancer (ABC) patients (pts) treated with alpelisib plus endocrine therapy (ALP+ET): An exploratory analysis of the METALLICA trial

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathologic complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomized, open-label, phase 2 trial

HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial

Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.

Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Prospective evaluation of predictive biomarkers for palbociclib and endocrine therapy benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breat cancer patients from PARSIFAL clinical trial: the transFAL sub-study

Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.

Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.

PHASE II Study To Assess The Efficacy Of Niraparib Rechallenge Treatment After Complete Secondary Cytoreduction In Ovarian Cancer Patients With Oligometastatic Progression: The ANALLISA Study